Filtered By:
Condition: Bleeding
Management: Insurance

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 143 results found since Jan 2013.

Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study.
CONCLUSION:  In the first study of a nationwide population cohort, we show that compliance with the simple ABC pathway is associated with improved clinically relevant outcomes of patients with AF. Given the high health care burden associated with AF, such a streamlined holistic approach to AF management should be implemented, to improve the care of such patients. PMID: 31266082 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 1, 2019 Category: Hematology Authors: Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Joung B, Lip GYH Tags: Thromb Haemost Source Type: research

Major ischaemic and bleeding risks following current drug-eluting stent implantation: Are there differences across current drug-eluting stent types in real life?
CONCLUSIONS: In real life, major ischaemic and bleeding risks do not differ across the various c-DESs over the first year following implantation. Future studies are needed to assess comparative c-DES effectiveness and safety longer term. PMID: 31262635 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - June 27, 2019 Category: Cardiology Authors: Schapiro-Dufour E, Tricotel A, Slama MS, Ducimetière P, Trinh-Duc A, Sichel C, Le Tri T, Galmiche H, Dray-Spira R, Zureik M Tags: Arch Cardiovasc Dis Source Type: research

Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case –Control Study
ConclusionOur study shows that the use of medications inhibiting serotonin and/or noradrenaline reuptake increases the risk of HS in patients aged 65  years and older and that the risk varies across individual ADs.
Source: Drug Safety - June 3, 2019 Category: Drugs & Pharmacology Source Type: research

Effectiveness and Safety of Four Direct Oral Anticoagulants in Asians with Non-valvular Atrial Fibrillation.
CONCLUSIONS: In the largest real-world practice study among Asians with NVAF, four DOACs were associated with lower risks of thromboembolism and bleeding than warfarin. There was consistency even amongst high risk subgroups and whether standard dose or low dose regimes were compared. PMID: 31103697 [PubMed - as supplied by publisher]
Source: Chest - May 15, 2019 Category: Respiratory Medicine Authors: Chan YH, Lee HF, See LC, Tu HT, Chao TF, Yeh YH, Wu LS, Kuo CT, Chang SH, Lip GYH Tags: Chest Source Type: research

Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
CONCLUSION: This study demonstrated the value of supplementing longitudinal site-based clinical studies with administrative claims data. Our results suggest that claims data together with network partner electronic health record data constitute an effective vehicle to capture patient outcomes since >30% of patients have non-fatal and fatal events outside of enrolling sites. PMID: 31081367 [PubMed - as supplied by publisher]
Source: Clinical Trials - May 12, 2019 Category: Research Authors: Ma Q, Chung H, Shambhu S, Roe M, Cziraky M, Jones WS, Haynes K Tags: Clin Trials Source Type: research

Stroke Prophylaxis for Atrial Fibrillation? To Prescribe or Not to Prescribe—A Qualitative Study on the Decisionmaking Process of Emergency Department Providers
ConclusionThe decision to prescribe oral anticoagulation in the ED is complex. Improving guideline adherence will require a multifaceted approach inclusive of system-level improvements, physician education, and the development of ED-specific tools and guidelines.
Source: Annals of Emergency Medicine - May 11, 2019 Category: Emergency Medicine Source Type: research

Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease
AbstractPatients with non-valvular atrial fibrillation (NVAF) and chronic kidney disease (CKD) are at increased risk of stroke and bleeding. Although direct oral anticoagulant (DOAC) trials excluded patients with severe CKD, a growing portion of CKD patients have been starting DOACs and limited data from real-world outcome in this high-risk setting are available. The INSigHT registry included 632 consecutive NVAF patients that started apixaban (256 patients, 41%), dabigatran (245, 39%) and rivaroxaban (131, 20%) between 2012 and 2015. Based on creatinine clearance, two sub-cohorts were defined: (1) non-CKD group (CrCl 60 ...
Source: Internal and Emergency Medicine - May 8, 2019 Category: Emergency Medicine Source Type: research

Long-Term Clinical Outcome of Drug-Eluting vs. Bare-Metal Stent Implantation After Percutaneous Coronary Intervention in End-Stage Renal Disease Patients on Hemodialysis 　- Nationwide Cohort Study in Taiwan.
CONCLUSIONS: In patients on chronic hemodialysis, implantation of DES did not have a better clinical outcome than BMS. PMID: 31019157 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 22, 2019 Category: Cardiology Authors: Chen ML, Wu JL, Chen MY, Hsieh TC Tags: Circ J Source Type: research

Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.
CONCLUSIONS: The incremental healthcare costs incurred by patients with versus without stroke/SE was nearly twice as high as those of patients with versus without MB. Moreover, each additional year up to 4 years after the first event was associated with an incremental cost for patients with a stroke/SE or MB event compared to those without an event. PMID: 30939954 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 5, 2019 Category: Health Management Tags: J Med Econ Source Type: research

One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: From Korean Health Insurance Review and Assessment Data.
CONCLUSIONS: Among patients aged younger than 75 years, ticagrelor was associated with lower incidence of all-cause mortality. Stroke risk was also reduced in patients with a prescription for ticagrelor without an increase in bleeding risk. PMID: 30770037 [PubMed - in process]
Source: Journal of Cardiology - February 17, 2019 Category: Cardiology Authors: Kim C, Shin DH, Hong SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Hong MK, Park J, Lee H, Kim DS, Oh SK, Jang Y Tags: J Cardiol Source Type: research

Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database
ConclusionBetween 2011 and 2016, the use of guideline-conform antithrombotic therapy in Germany has significantly increased. This was associated with a significant decline in strokes without an increased incidence of bleeding complications.
Source: Clinical Research in Cardiology - February 15, 2019 Category: Cardiology Source Type: research

Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin.
Conclusion: The results of the study indicated that patients on DOACs had lower rates of ischemic stroke, hemorrhagic stroke, SE, and composite outcome of stroke or SE compared with patients on warfarin. No significant differences in bleeding rates between the DOAC and warfarin groups were observed, while total cost of care was lower in the DOAC group. PMID: 30698654 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - January 29, 2019 Category: Drugs & Pharmacology Authors: Datar M, Crivera C, Rozjabek H, Abbass IM, Xu Y, Pasquale MK, Schein JR, Andrews GA Tags: Am J Health Syst Pharm Source Type: research

Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation
ConclusionThis real ‐world study suggests that in the setting of polypharmacy and NVAF, rivaroxaban is an effective and safe alternative to warfarin.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 31, 2018 Category: Drugs & Pharmacology Authors: Brandon K. Martinez, William L. Baker, Nitesh A. Sood, Thomas J. Bunz, Anna ‐Katharina Meinecke, Daniel Eriksson, Craig I. Coleman Tags: Brief Report Source Type: research

Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort.
CONCLUSION: Dual antiplatelet or triple therapy increased the risk of VH significantly, compared to warfarin monotherapy. Considering the low efficacy of preventing ischemic stroke and high risk of bleeding, dual or triple therapy using warfarin and antiplatelet agents should be avoided to prevent VH in AF patients. PMID: 30554492 [PubMed - in process]
Source: Yonsei Medical Journal - December 18, 2018 Category: Universities & Medical Training Authors: Kim KE, Yang PS, Jang E, Kim S, Joung B Tags: Yonsei Med J Source Type: research